Рет қаралды 1,379
Erik Dubberke, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, compare the use of fidaxomicin against standard therapy options, such as vancomycin, for the treatment of Clostridium difficile, suggesting that fidaxomicin may reduce a patient’s risk of recurrence.